한빛사 논문
June Young Chuna, Sohyun Parkb, Jongheon Jungc, Su-Hyun Kimd, Tae-Sung Kimb, Young Ju Choia, Ho Jin Kimd, Hyeon-Seok Eomc,*, Jae-Won Hyund,*
aDivision of Infectious Disease, Department of Internal Medicine, Research Institute and Hospital of National Cancer Center, Goyang 10408, South Korea
bDepartment of Nuclear Medicine, Research Institute and Hospital of National Cancer Center, Goyang 10408, South Korea
cDepartment of Hemato-oncology, Research Institute and Hospital of National Cancer Center, Goyang 10408, South Korea
dCenter for Hematologic Malignancy, and Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang 10408, South Korea
JYC and SP contributed equally as first authors.
*To whom correspondence should be addressed.
Abstract
Guillain-Barré syndrome after vaccination against COVID-19 has been reported worldwide. Albeit rare, Guillain-Barré syndrome after vaccination is of great public concern given that it could potentially result in life-threatening paralysis. We report the findings of two patients with Guillain-Barré syndrome after receiving the BNT162b2 vaccine (tozinameran, Pfizer–BioNTech) who were in complete remission from diffuse large B-cell lymphoma.
논문정보
관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기